Allcott 2015 - Model of External Validity and Site Selection Bias
Summary
Extends Hotz, Imbens and Mortimer (2005): the target ATE is identified from sample data if unconfoundedness, overlap, external unconfoundedness and external overlap hold. With many sites, external unconfoundedness reduces to “no site selection bias” (Assumption 3B) — weaker than homogeneous site effects, but guaranteed only by random or quasi-random site selection.
Overview
Rubin causal model: treatment; potential outcomes ; ; covariates; equals 1 if is in the sample population (treated/evaluated), 0 if in the target population.
Main Content
3.1 External validity
Assumptions 1-4
- Unconfoundedness: .
- Overlap: .
- External unconfoundedness: .
- External overlap: .
Transport of the ATE
If Assumptions 1-4 hold on the support of in the target population,
Proof sketch (footnote 5; follows Hotz-Imbens-Mortimer Lemma 1): the two unconfoundedness assumptions imply for each : . The overlap assumptions make it feasible to average over the target distribution of .
Two differences from Hotz et al.: (i) (1) does not require random assignment within sample sites, so it covers quasi-experiments; (ii) external unconfoundedness is a weaker version of their “unconfounded location” assumption ; only the difference in potential outcomes must be independent of . The stronger version motivates testing , but that is theoretically neither necessary nor sufficient, and in Opower it is uninformative because untreated usage mostly reflects weather variation (Appendix C).
3.2 Sites, replication and site selection bias
Site
A setting in which a programme might be implemented or evaluated, comprising a population of individuals, a treatment as implemented (), and an economic environment (). = site of individual ; . indicates a sample site.
Selection operates at site level in Opower (whole sites are in sample or in target).
Assumption 3A - homogeneous site effects
for a pair of sites. Equivalent to external unconfoundedness when extrapolating from one sample site to one target site. Rarely plausible; made implicitly whenever single-site results are applied elsewhere.
Assumption 3B - no site selection bias
over a large number of sites. Equivalent to external unconfoundedness for many sample and many target sites; weaker than 3A because site heterogeneity is allowed if it “averages out”.
Site selection bias
The failure of external unconfoundedness when sites enter the sample through mechanisms other than random or quasi-random assignment. The word “bias” does not mean sample-site effect estimates are wrong for those sites; it means sample effects differ systematically from target effects.
- 3B is guaranteed by random site assignment (e.g., JTPA hoped to randomize sites within 20 strata of size, region and programme quality) or quasi-random assignment (Moving to Opportunity and the RAND Health Insurance Experiment chose cities for diversity).
- Replication helps only if replication sites are chosen randomly or quasi-randomly.
- Site selection bias is distinct from the within-sample heterogeneity underlying LATE: such heterogeneity is neither necessary nor sufficient for site selection bias (footnote 9 offers the analogy of a site as a set of compliers; bias arises when available instruments systematically identify populations whose LATEs differ from the target ATE).
- 3A holding across all sites is sufficient for 3B, so significant dispersion of site effects is a necessary precondition for site selection bias (Allcott 2015 - Opower Program, Selection Mechanisms and Data).
Examples
- With 111 sites, 3B implies the average over early (sample) sites equals the average over late (target) sites, which is directly testable with the metadata (Allcott 2015 - Microdata Extrapolation and the Prediction Failure).
Connections
- Individual-level analogue: conditions (4)-(5) in Dahabreh 2020 - Identifiability Conditions and Identification (his = sample indicator, here ).
- The Experimental Ideal — internal validity via randomization; this note is the external-validity counterpart.